{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:54Z","timestamp":1790369994949,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02371-5","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:23:14Z","timestamp":1787142194000},"page":"1599-1618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alopecia Areata: Current and Emerging Therapies"],"prefix":"10.1007","volume":"86","author":[{"given":"Jo\u00e3o","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"16","key":"2371_CR1","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"A Gilhar","year":"2012","unstructured":"Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515\u201325. https:\/\/doi.org\/10.1056\/NEJMra1103442.","journal-title":"N Engl J Med"},{"issue":"4","key":"2371_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014;134(4):1141\u20132. https:\/\/doi.org\/10.1038\/jid.2013.464.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2371_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","volume":"159","author":"A Mostaghimi","year":"2023","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. JAMA Dermatol. 2023;159(4):411\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2023.0002.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2371_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamadermatol.2022.0351","volume":"158","author":"PL McKenzie","year":"2022","unstructured":"McKenzie PL, Maltenfort M, Bruckner AL, et al. Evaluation of the prevalence and incidence of pediatric alopecia areata using electronic health record data. JAMA Dermatol. 2022;158(5):547\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0351.","journal-title":"JAMA Dermatol"},{"key":"2371_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-025-00664-9","volume":"11","author":"B Ungar","year":"2025","unstructured":"Ungar B, Renert-Yuval Y, Dlova NC, Jabbari A, King B, Mesinkovska NA, et al. Alopecia areata. Nat Rev Dis Primers. 2025;11:77. https:\/\/doi.org\/10.1038\/s41572-025-00664-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2371_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394. https:\/\/doi.org\/10.1111\/jdv.19768.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"2371_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/ijd.13866","volume":"57","author":"K Chelidze","year":"2018","unstructured":"Chelidze K, Lipner SR. Nail changes in alopecia areata: an update and review. Int J Dermatol. 2018;57(7):776\u201383. https:\/\/doi.org\/10.1111\/ijd.13866.","journal-title":"Int J Dermatol"},{"key":"2371_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"AC Villasante Fricke","year":"2015","unstructured":"Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397\u2013403. https:\/\/doi.org\/10.2147\/CCID.S53985.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"8","key":"2371_CR9","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/jdv.18926","volume":"37","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Walen S, Nunez-Cruz S, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023;37(8):1490\u2013520. https:\/\/doi.org\/10.1111\/jdv.18926.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2371_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jamadermatol.2018.4398","volume":"155","author":"IA Vallerand","year":"2019","unstructured":"Vallerand IA, Lewinson RT, Parsons LM, et al. Assessment of a bidirectional association between major depressive disorder and alopecia areata. JAMA Dermatol. 2019;155(4):475\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2018.4398.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2371_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ced\/llac104","volume":"48","author":"S Holmes","year":"2023","unstructured":"Holmes S, Harries M, et al. Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study. Clin Exp Dermatol. 2023;48(4):325\u201331. https:\/\/doi.org\/10.1093\/ced\/llac104.","journal-title":"Clin Exp Dermatol"},{"key":"2371_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.1578","author":"CG Bunick","year":"2025","unstructured":"Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, et al. The epidemiology of atopic dermatitis among adults and adolescents with alopecia areata in the United States. J Invest Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1578.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2371_CR13","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/jdv.16864","volume":"35","author":"RRZ Conic","year":"2021","unstructured":"Conic RRZ, Chu S, Tamashunas NL, Damiani G. Prevalence of cardiac and metabolic diseases among patients with alopecia areata. J Eur Acad Dermatol Venereol. 2021;35(2):e128\u20139. https:\/\/doi.org\/10.1111\/jdv.16864.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2371_CR14","doi-asserted-by":"publisher","first-page":"c3671","DOI":"10.1136\/bmj.c3671","volume":"341","author":"MJ Harries","year":"2010","unstructured":"Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010;341:c3671. https:\/\/doi.org\/10.1136\/bmj.c3671.","journal-title":"BMJ"},{"issue":"2","key":"2371_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010;62(2):191\u2013202. https:\/\/doi.org\/10.1016\/j.jaad.2009.10.031. (quiz 203\u2013204).","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2371_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","volume":"164","author":"T Ito","year":"2004","unstructured":"Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol. 2004;164(2):623\u201334. https:\/\/doi.org\/10.1016\/S0002-9440(10)63151-3.","journal-title":"Am J Pathol"},{"key":"2371_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1681163","volume":"16","author":"SY Kim","year":"2025","unstructured":"Kim SY, et al. Alopecia areata: from immunopathogenesis to emerging therapeutic approaches. Front Immunol. 2025;16:1681163. https:\/\/doi.org\/10.3389\/fimmu.2025.1681163.","journal-title":"Front Immunol"},{"key":"2371_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621492","volume":"16","author":"HB Zhao","year":"2025","unstructured":"Zhao HB, et al. From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology. Front Immunol. 2025;16:1621492. https:\/\/doi.org\/10.3389\/fimmu.2025.1621492.","journal-title":"Front Immunol"},{"issue":"9","key":"2371_CR19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139. https:\/\/doi.org\/10.1038\/nm.3645.","journal-title":"Nat Med"},{"key":"2371_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1577115","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li Q, Zhang Y, Liu Y. Janus kinase inhibitors for alopecia areata: a review of clinical data. Front Immunol. 2025;16:1577115. https:\/\/doi.org\/10.3389\/fimmu.2025.1577115.","journal-title":"Front Immunol"},{"issue":"5","key":"2371_CR21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","volume":"142","author":"T Song","year":"2018","unstructured":"Song T, et al. An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol. 2018;142(5):1631-1634.e13. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2371_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","volume":"84","author":"JW Glickman","year":"2021","unstructured":"Glickman JW, Dubin C, Renert-Yuval Y, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol. 2021;84(2):370\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2371_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.18883","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator\u2019s Global Assessment (AA-IGA) scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020;183(4):702\u20139. https:\/\/doi.org\/10.1111\/bjd.18883.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2371_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.043.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2371_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2019.11.066","volume":"82","author":"BE Yee","year":"2020","unstructured":"Yee BE, Tong Y, Goldenberg A, Hata T. Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(4):1018\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.066.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2371_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14555","volume":"34","author":"M Rajan","year":"2021","unstructured":"Rajan M, Sharma AN, Boespflug A, Kaliyadan F. Intralesional corticosteroids in alopecia areata: a comparative study of different concentrations and a proposed step-up regimen. Dermatol Ther. 2021;34(3):e14555. https:\/\/doi.org\/10.1111\/dth.14555.","journal-title":"Dermatol Ther"},{"issue":"1","key":"2371_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1067\/mjd.2003.423","volume":"49","author":"A Tosti","year":"2003","unstructured":"Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis. J Am Acad Dermatol. 2003;49(1):96\u20138. https:\/\/doi.org\/10.1067\/mjd.2003.423.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2371_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403\u201323. https:\/\/doi.org\/10.1007\/s12016-021-08883-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"2371_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaad.2015.12.026","volume":"74","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2016","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. J Am Acad Dermatol. 2016;74(5):1005\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.026.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2371_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1001\/jamadermatol.2022.6687","volume":"159","author":"P Joly","year":"2023","unstructured":"Joly P, Lafon A, Houivet E, et al. Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial. JAMA Dermatol. 2023;159(4):403\u201310. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6687.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2371_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2004.10.873","volume":"52","author":"BR Kar","year":"2005","unstructured":"Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol. 2005;52(2):287\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2004.10.873.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2371_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2015.09.045","volume":"74","author":"R Shreberk-Hassidim","year":"2016","unstructured":"Shreberk-Hassidim R, Ramot Y, Gilula Z, Zlotogorski A. A systematic review of pulse steroid therapy for alopecia areata. J Am Acad Dermatol. 2016;74(2):372-374.e5. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.045.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2371_CR33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","volume":"154","author":"S Lee","year":"2018","unstructured":"Lee S, Kim BJ, Lee YB, Lee WS. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2018.2312.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2371_CR34","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaad.2025.05.1446","volume":"93","author":"L Kalil","year":"2025","unstructured":"Kalil L, Valido K, Peterson D, King B. Oral minoxidil treatment of alopecia areata. J Am Acad Dermatol. 2025;93(4):1099\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1446.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2371_CR35","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/archderm.123.11.1488","volume":"123","author":"VC Fiedler-Weiss","year":"1987","unstructured":"Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1488\u201390. https:\/\/doi.org\/10.1001\/archderm.123.11.1488.","journal-title":"Arch Dermatol"},{"issue":"4","key":"2371_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaad.2025.05.1393","volume":"93","author":"K Valido","year":"2025","unstructured":"Valido K, Kalil L, Peterson D, King B. Combination oral minoxidil and baricitinib treatment of alopecia areata. J Am Acad Dermatol. 2025;93(4):1071\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1393.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.157","author":"J Jimenez-Cauhe","year":"2025","unstructured":"Jimenez-Cauhe J, et al. Combination of oral minoxidil and baricitinib for alopecia areata: a retrospective study of 77 patients. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.10.157.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2371_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.jaad.2004.05.026","volume":"51","author":"W Zakaria","year":"2004","unstructured":"Zakaria W, Passeron T, Ostovari N, Lacour JP, Ortonne JP. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol. 2004;51(5):837\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2004.05.026.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2371_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1365-2133.2005.06320.x","volume":"152","author":"F Aubin","year":"2005","unstructured":"Aubin F, Vigan M, Puzenat E, Blanc D, Drobacheff C, Deprez P, et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol. 2005;152(1):99\u2013103. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06320.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2371_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.004.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2371_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","volume":"46","author":"L Chikhoune","year":"2025","unstructured":"Chikhoune L, et al. JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases. Rev Med Interne. 2025;46(2):89\u2013106. https:\/\/doi.org\/10.1016\/j.revmed.2024.10.452.","journal-title":"Rev Med Interne"},{"key":"2371_CR42","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2025-7-10","author":"B Henriques Dos Santos","year":"2025","unstructured":"Henriques Dos Santos B, et al. JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review. Drugs Context. 2025. https:\/\/doi.org\/10.7573\/dic.2025-7-10.","journal-title":"Drugs Context."},{"issue":"5","key":"2371_CR43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40261-023-01260-z","volume":"43","author":"M Papierzewska","year":"2023","unstructured":"Papierzewska M, Wa\u015bkiel-Burnat A, Rudnicka L. Safety of Janus kinase inhibitors in patients with alopecia areata: a systematic review. Clin Drug Investig. 2023;43(5):325\u201334. https:\/\/doi.org\/10.1007\/s40261-023-01260-z.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"2371_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500973","volume":"1","author":"S Harel","year":"2015","unstructured":"Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. https:\/\/doi.org\/10.1126\/sciadv.1500973.","journal-title":"Sci Adv"},{"issue":"2","key":"2371_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2024","unstructured":"Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2024;192(2):190\u2013205. https:\/\/doi.org\/10.1093\/bjd\/ljae385.","journal-title":"Br J Dermatol"},{"key":"2371_CR46","unstructured":"Medicines and Healthcare products Regulatory Agency. MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults [Internet]. London: MHRA; 2026 [cited 2026 Jul]. https:\/\/www.gov.uk\/government\/news."},{"issue":"9","key":"2371_CR47","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","volume":"83","author":"E Freitas","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761\u201370. https:\/\/doi.org\/10.1007\/s40265-023-01873-w.","journal-title":"Drugs"},{"issue":"18","key":"2371_CR48","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"issue":"3","key":"2371_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00764-w.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"2371_CR50","doi-asserted-by":"publisher","first-page":"s662","DOI":"10.25251\/t6v95c18","volume":"9","author":"RA Vleugels","year":"2025","unstructured":"Vleugels RA, Piraccini BM, Mesinkovska N, Mostaghimi A, Shimomura Y, Sontag A, et al. Baricitinib provides sustained, long-term efficacy with consistent safety for up to 5 years of treatment in adults with severe alopecia areata: final results from BRAVE-AA1 and BRAVE-AA2. SKIN J Cutan Med. 2025;9(6):s662. https:\/\/doi.org\/10.25251\/t6v95c18.","journal-title":"SKIN J Cutan Med"},{"issue":"10","key":"2371_CR51","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2772","volume":"160","author":"B King","year":"2024","unstructured":"King B, Kwon O, Mesinkovska NA, et al. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024;160(10):1075\u201381. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2772.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2371_CR52","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad253.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2371_CR53","doi-asserted-by":"publisher","first-page":"2444494","DOI":"10.1080\/09546634.2024.2444494","volume":"36","author":"CA Vignoli","year":"2025","unstructured":"Vignoli CA, Starace M, Bardazzi F, et al. Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study. J Dermatolog Treat. 2025;36(1):2444494. https:\/\/doi.org\/10.1080\/09546634.2024.2444494.","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"2371_CR54","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s13555-025-01425-y","volume":"15","author":"J Seneschal","year":"2025","unstructured":"Seneschal J, Nart F, Dabral S, et al. Real-world evidence for baricitinib in the treatment of atopic dermatitis and alopecia areata: systematic literature review 2020\u20132023. Dermatol Ther (Heidelb). 2025;15(7):1719\u201354. https:\/\/doi.org\/10.1007\/s13555-025-01425-y.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"2371_CR55","unstructured":"Eli Lilly and Company. Lilly\u2019s baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in phase 3 BRAVE-AA-PEDS study [Internet]. Indianapolis : Eli Lilly and Company; 2025. http:\/\/lilly.mediaroom.com\/2025-03-08-Lillys-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alopecia-areata-in-Phase-3-BRAVE-AA-PEDS-study."},{"key":"2371_CR56","unstructured":"ClinicalTrials.gov. A study of baricitinib (LY3009104) in children from 6 years to less than 18 years of age with alopecia areata (BRAVE-AA-PEDS) [Internet]. Bethesda (MD): National Library of Medicine (US); 2025. http:\/\/clinicaltrials.gov\/study\/NCT05723198."},{"issue":"14","key":"2371_CR57","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA. Ritlecitinib: first approval. Drugs. 2023;83(14):1315\u201321. https:\/\/doi.org\/10.1007\/s40265-023-01928-y.","journal-title":"Drugs"},{"issue":"10387","key":"2371_CR58","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-4","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-4.","journal-title":"Lancet"},{"issue":"6","key":"2371_CR59","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jdv.20526","volume":"39","author":"C Tziotzios","year":"2025","unstructured":"Tziotzios C, Sinclair R, Shapiro J, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025;39(6):1152\u201362. https:\/\/doi.org\/10.1111\/jdv.20526.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2371_CR60","doi-asserted-by":"publisher","DOI":"10.25251\/0nqf0x70","volume":"9","author":"M Senna","year":"2025","unstructured":"Senna M, King B, Craiglow B, et al. Updated integrated safety analysis of ritlecitinib over 72 months in patients with alopecia areata. SKIN J Cutan Med. 2025;9(6):s658. https:\/\/doi.org\/10.25251\/0nqf0x70.","journal-title":"SKIN J Cutan Med."},{"issue":"6","key":"2371_CR61","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jdv.20547","volume":"39","author":"B King","year":"2025","unstructured":"King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163\u201373. https:\/\/doi.org\/10.1111\/jdv.20547.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2371_CR62","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaad.2025.06.041","volume":"93","author":"W Zhang","year":"2025","unstructured":"Zhang W, Li X, Zhang Y, Luo Y, Li H, Zhou C. Ritlecitinib in alopecia areata: a multicenter retrospective real-world analysis. J Am Acad Dermatol. 2025;93(4):1136\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.041.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2371_CR63","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/ced\/llaf128","volume":"50","author":"L Valtellini","year":"2025","unstructured":"Valtellini L, Balestri R, Bardazzi F, et al. Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study. Clin Exp Dermatol. 2025;50(11):2297\u2013300. https:\/\/doi.org\/10.1093\/ced\/llaf128.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2371_CR64","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2025.09.008","volume":"94","author":"X Wang","year":"2026","unstructured":"Wang X, Liu Y, Sun Y, Ma L, Xu Z, Zhang B. Ritlecitinib for severe alopecia areata in children under 12 years: a retrospective review of 18 cases. J Am Acad Dermatol. 2026;94(1):280\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.008.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR65","unstructured":"ClinicalTrials.gov. A study of 2 doses of ritlecitinib in people 12 years and older with alopecia areata [Internet]. Bethesda (MD): National Library of Medicine (US); 2025. http:\/\/clinicaltrials.gov\/study\/NCT06873945."},{"key":"2371_CR66","unstructured":"ClinicalTrials.gov. A study to learn about medicine called ritlecitinib in children 6 to less than 12 years of age with severe alopecia areata [Internet]. Bethesda (MD): National Library of Medicine (US); 2025. http:\/\/clinicaltrials.gov\/study\/NCT07029711."},{"issue":"5","key":"2371_CR67","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Kwon O, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097.","journal-title":"J Am Acad Dermatol."},{"key":"2371_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.11.070","author":"A Tsianakas","year":"2025","unstructured":"Tsianakas A, Kwon O, Sinclair R, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3 randomized double-blind controlled trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.11.070.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR69","unstructured":"U.S. Food and Drug Administration.\u00a0LEQSELVI (deuruxolitinib)\u00a0[Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a603f231-d09e-4bad-ad5e-b55f865da095."},{"key":"2371_CR70","unstructured":"ClinicalTrials.gov.\u00a0A study of deuruxolitinib in pediatric participants aged 12 to <18 years with alopecia areata (NCT07133308)\u00a0[Internet]. Bethesda (MD): National Library of Medicine (US); 2025. https:\/\/clinicaltrials.gov\/study\/NCT07133308."},{"issue":"5","key":"2371_CR71","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"C Zhou","year":"2023","unstructured":"Zhou C, Luo Y, Zhang Y, et al. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata. J Am Acad Dermatol. 2023;89(5):911\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.02.063.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR72","unstructured":"PharmCube.\u00a0Hengrui\u2019s JAK1 inhibitor ivarmacitinib approved in China for severe alopecia areata\u00a0[Internet]. PharmCube Global Drug News. 2025. https:\/\/global.pharmcube.com\/news\/detail\/58378c52fc8d457daff50d06f00100a0."},{"key":"2371_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.044","author":"C Zhou","year":"2025","unstructured":"Zhou C, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: results from a phase 3 trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.044.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR74","unstructured":"ClinicalTrials.gov.\u00a0A study to evaluate the efficacy and safety of upadacitinib in adults and adolescents with severe alopecia areata (NCT06012240)\u00a0[Internet]. Bethesda (MD): National Library of Medicine (US); 2023. https:\/\/clinicaltrials.gov\/study\/NCT06012240."},{"key":"2371_CR75","unstructured":"ClinicalTrials.gov.\u00a0A phase 3 randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with alopecia areata and at least 25% scalp hair loss (NCT07023302)\u00a0[Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/study\/NCT07023302."},{"key":"2371_CR76","unstructured":"Dermatology Times.\u00a0Upadacitinib shows strong efficacy in second pivotal phase 3 study for severe alopecia areata\u00a0[Internet]. 2025. https:\/\/www.dermatologytimes.com\/view\/upadacitinib-shows-strong-efficacy-in-second-pivotal-phase-3-study-for-severe-alopecia-areata."},{"issue":"2","key":"2371_CR77","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2371_CR78","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1093\/ced\/llaf345","volume":"50","author":"SS Yong","year":"2025","unstructured":"Yong SS, Bhoyrul B. Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib. Clin Exp Dermatol. 2025;50(12):2501\u20132. https:\/\/doi.org\/10.1093\/ced\/llaf345.","journal-title":"Clin Exp Dermatol"},{"key":"2371_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231213135","author":"S Oliel","year":"2023","unstructured":"Oliel S, Moussa S, Stanciu M, Netchiporouk E. Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: a case report. SAGE Open Med Case Rep. 2023. https:\/\/doi.org\/10.1177\/2050313X231213135.","journal-title":"SAGE Open Med Case Rep."},{"key":"2371_CR80","unstructured":"ClinicalTrials.gov. A study to evaluate efficacy and safety of deucravacitinib in participants with alopecia areata (NCT05556265) [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. http:\/\/clinicaltrials.gov\/study\/NCT05556265."},{"issue":"12","key":"2371_CR81","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988\u201390. https:\/\/doi.org\/10.1038\/jid.2014.260.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2371_CR82","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ajd.14325","volume":"65","author":"W Cranwell","year":"2024","unstructured":"Cranwell W, Lai VWY, Photiou L, et al. Real-world effectiveness and safety of tofacitinib for alopecia areata: a retrospective cohort study of 202 patients. Australas J Dermatol. 2024;65(6):505\u201313. https:\/\/doi.org\/10.1111\/ajd.14325.","journal-title":"Australas J Dermatol"},{"issue":"15","key":"2371_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. https:\/\/doi.org\/10.1172\/jci.insight.89776.","journal-title":"JCI Insight"},{"issue":"1","key":"2371_CR84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2371_CR85","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","volume":"80","author":"BG Craiglow","year":"2019","unstructured":"Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019;80(2):568\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.041.","journal-title":"J Am Acad Dermatol"},{"key":"2371_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15882","author":"R Mahajan","year":"2025","unstructured":"Mahajan R, Mehta H, Gupta A, et al. Oral tofacitinib for the management of moderate to severe alopecia areata in children and adolescents: a retrospective study of 36 patients. Pediatr Dermatol. 2025. https:\/\/doi.org\/10.1111\/pde.15882.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2371_CR87","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/ijt.ijt_101_24","volume":"17","author":"M Ranjbaryan","year":"2025","unstructured":"Ranjbaryan M, Weisenseel P, Karsai SA. Efficacy of tofacitinib in alopecia areata\u2014lucky punch or robust treatment option? Int J Trichol. 2025;17(3):245\u20137. https:\/\/doi.org\/10.4103\/ijt.ijt_101_24.","journal-title":"Int J Trichol"},{"issue":"2","key":"2371_CR88","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","volume":"80","author":"LY Liu","year":"2019","unstructured":"Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.040.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"2371_CR89","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. https:\/\/doi.org\/10.1172\/jci.insight.89790.","journal-title":"JCI Insight"},{"issue":"4","key":"2371_CR90","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jdcr.2020.02.007","volume":"6","author":"DM Peterson","year":"2020","unstructured":"Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep. 2020;6(4):257\u20139. https:\/\/doi.org\/10.1016\/j.jdcr.2020.02.007.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"2371_CR91","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaad.2024.09.025","volume":"92","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang F, Li X, et al. Oral abrocitinib for treatment of refractory alopecia areata: a retrospective study. J Am Acad Dermatol. 2025;92(1):153\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.025.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2371_CR92","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jocd.15896","volume":"23","author":"J Huang","year":"2024","unstructured":"Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib. J Cosmet Dermatol. 2024;23(1):348\u20139. https:\/\/doi.org\/10.1111\/jocd.15896.","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"2371_CR93","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.abd.2024.11.004","volume":"100","author":"J Lin","year":"2025","unstructured":"Lin J, Li Z, Shen L, et al. Successful treatment of severe diffuse alopecia areata with abrocitinib. An Bras Dermatol. 2025;100(3):580\u20132. https:\/\/doi.org\/10.1016\/j.abd.2024.11.004.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"2371_CR94","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2242706","volume":"34","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zuo YG. Successful treatment of alopecia universalis with abrocitinib: a case report. J Dermatolog Treat. 2023;34(1):2242706. https:\/\/doi.org\/10.1080\/09546634.2023.2242706.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"2371_CR95","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ajd.13836","volume":"63","author":"M Bennett","year":"2022","unstructured":"Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. Australas J Dermatol. 2022;63(2):274\u20136. https:\/\/doi.org\/10.1111\/ajd.13836.","journal-title":"Australas J Dermatol"},{"key":"2371_CR96","unstructured":"ClinicalTrials.gov. Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndrome (NCT07242638) [Internet]. Bethesda (MD): National Library of Medicine (US); 2025. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT07242638."},{"key":"2371_CR97","unstructured":"ClinicalTrials.gov. Efficacy and safety of JAK inhibitors in patients with alopecia areata: a single-center, real-world study (NCT06573593) [Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/study\/NCT06573593"},{"issue":"2","key":"2371_CR98","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2019.10.016","volume":"82","author":"EA Olsen","year":"2020","unstructured":"Olsen EA, Kornacki D, Sun K, et al. Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2020;82(2):412\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.016.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2371_CR99","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00403-022-02336-0","volume":"315","author":"D Mikhaylov","year":"2023","unstructured":"Mikhaylov D, Pavel AB, Yao C, et al. A phase 2a randomized vehicle-controlled multicenter study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2023;315(2):181\u20139. https:\/\/doi.org\/10.1007\/s00403-022-02336-0.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"2371_CR100","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403-404.e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.043.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2371_CR101","doi-asserted-by":"publisher","first-page":"AB255","DOI":"10.1016\/j.jaad.2025.05.1012","volume":"93","author":"M Lebwohl","year":"2025","unstructured":"Lebwohl M, Collins E, et al. 62202. Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score. J Am Acad Dermatol. 2025;93(3):AB255. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1012.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2371_CR102","doi-asserted-by":"publisher","first-page":"2312245","DOI":"10.1080\/09546634.2024.2312245","volume":"35","author":"J Huang","year":"2024","unstructured":"Huang J, Wang Y, Luo Y, et al. Dupilumab therapy for alopecia areata: a case series and review of the literature. J Dermatolog Treat. 2024;35(1):2312245. https:\/\/doi.org\/10.1080\/09546634.2024.2312245.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"2371_CR103","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaad.2025.05.1387","volume":"93","author":"A Srivatsa","year":"2025","unstructured":"Srivatsa A, Romanski MG, Rehman W, Graham S, Rehman R, Moossavi M, et al. Friend or foe: a systematic review of dupilumab and alopecia areata. J Am Acad Dermatol. 2025;93(3):825\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1387.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2371_CR104","doi-asserted-by":"publisher","first-page":"e2024270","DOI":"10.5826\/dpc.1404a270","volume":"14","author":"M Starace","year":"2024","unstructured":"Starace M, Cedirian S, Quadrelli F, Pampaloni F, Brunetti T, Chessa MA, et al. Dupilumab and alopecia areata: a possible combined or disturbance therapy? A review of the literature. Dermatol Pract Concept. 2024;14(4):e2024270. https:\/\/doi.org\/10.5826\/dpc.1404a270.","journal-title":"Dermatol Pract Concept"},{"issue":"4","key":"2371_CR105","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jaip.2020.01.052","volume":"8","author":"K Kridin","year":"2020","unstructured":"Kridin K, Renert-Yuval Y, Guttman-Yassky E, Cohen AD. Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients. J Allergy Clin Immunol Pract. 2020;8(4):1323-1328.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.01.052.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2371_CR106","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","volume":"77","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients. Allergy. 2022;77(3):897\u2013906. https:\/\/doi.org\/10.1111\/all.15071.","journal-title":"Allergy"},{"key":"2371_CR107","unstructured":"ClinicalTrials.gov. Regeneron AA Multicenter (Dupilumab) (NCT05551793) [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. https:\/\/clinicaltrials.gov\/study\/NCT05551793."},{"key":"2371_CR108","unstructured":"ClinicalTrials.gov. Dupilumab in the treatment of pediatric alopecia areata (NCT05866562) [Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/study\/NCT05866562."},{"issue":"1","key":"2371_CR109","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.det.2024.09.001","volume":"43","author":"L Kalil","year":"2025","unstructured":"Kalil L, King B. Innovation in alopecia areata. Dermatol Clin. 2025;43(1):27\u201333. https:\/\/doi.org\/10.1016\/j.det.2024.09.001.","journal-title":"Dermatol Clin"},{"key":"2371_CR110","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of rosnilimab (ANB030) in treatment of subjects with moderate-to-severe alopecia areata (AZURE) (NCT05205070) [Internet]. Bethesda (MD): National Library of Medicine (US); 2021. https:\/\/clinicaltrials.gov\/study\/NCT05205070."},{"issue":"4","key":"2371_CR111","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp K, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2371_CR112","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1111\/all.16268","volume":"79","author":"M Kim","year":"2024","unstructured":"Kim M, Del Duca E, Pavel AB, et al. Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds. Allergy. 2024;79(12):3401\u201314. https:\/\/doi.org\/10.1111\/all.16268.","journal-title":"Allergy"},{"key":"2371_CR113","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata (NCT06444451) [Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/study\/NCT06444451."},{"issue":"1","key":"2371_CR114","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","volume":"234","author":"W Cao","year":"2010","unstructured":"Cao W, Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev. 2010;234(1):163\u201376. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00867.x.","journal-title":"Immunol Rev"},{"key":"2371_CR115","unstructured":"ClinicalTrials.gov. Study of DAXDILIMAB for the treatment of moderate to severe alopecia areata (NCT05368103) [Internet]. Bethesda (MD): National Library of Medicine (US); 2022. https:\/\/clinicaltrials.gov\/study\/NCT05368103."},{"issue":"2","key":"2371_CR116","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/jcph.1522","volume":"60","author":"PA Frohna","year":"2020","unstructured":"Frohna PA, Brown M, Halfpenny KC, et al. Results from a first-in-human study of BNZ-1, a selective multicytokine inhibitor targeting members of the common gamma (\u03b3c) family of cytokines. J Clin Pharmacol. 2020;60(2):264\u201373. https:\/\/doi.org\/10.1002\/jcph.1522.","journal-title":"J Clin Pharmacol"},{"key":"2371_CR117","unstructured":"ClinicalTrials.gov. A randomized, double-blind, placebo-controlled phase 2 trial of intravenous BNZ-1 in patients with moderate to severe alopecia areata (NCT05589610) [Internet]. Bethesda (MD): National Library of Medicine (US); 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05589610."},{"key":"2371_CR118","unstructured":"Equillium Inc. Equillium announces positive topline data from phase 2 study of EQ101 in alopecia areata [Internet]. 2024. https:\/\/www.equilliumbio.com\/investors\/press-releases\/news-details\/2024\/Equillium-Announces-Positive-Topline-Data-from-Phase-2-Study-of-EQ101-in-Alopecia-Areata\/default.aspx."},{"issue":"10383","key":"2371_CR119","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00061-2.","journal-title":"Lancet"},{"issue":"6","key":"2371_CR120","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.20605","volume":"39","author":"B King","year":"2025","unstructured":"King B, Mesinkovska N, Senna M, et al. Efficacy and safety of etrasimod in alopecia areata: a multicentre, randomized, double-blind, placebo-controlled, Phase 2 study. J Eur Acad Dermatol Venereol. 2025;39(6):1174\u201384. https:\/\/doi.org\/10.1111\/jdv.20605.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2371_CR121","unstructured":"ClinicalTrials.gov. A multi-center, randomized, double-blind, placebo-controlled, phase 2a study to evaluate the efficacy and safety of NXC736 in patients with moderate and severe alopecia areata (NCT06104839) [Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06104839."},{"issue":"14","key":"2371_CR122","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd1866","volume":"7","author":"Z Dai","year":"2021","unstructured":"Dai Z, Xing L, Cerise JE, et al. Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H\/HeJ mice. Sci Adv. 2021;7(14):eabd1866. https:\/\/doi.org\/10.1126\/sciadv.abd1866.","journal-title":"Sci Adv"},{"key":"2371_CR123","unstructured":"Healio. Bempikibart may incite hair regrowth after treatment cessation in severe alopecia areata [Internet]. Thorofare (NJ): Healio; 2025 Mar 10. https:\/\/www.healio.com\/news\/dermatology\/20250310\/bempikibart-may-incite-hair-regrowth-after-treatment-cessation-in-severe-alopecia-areata."},{"key":"2371_CR124","unstructured":"ClinicalTrials.gov. A phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept trial with part B and open-label extension of bempikibart (ADX-914) for the treatment of severe alopecia areata (SIGNAL-AA) (NCT06018428) [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06018428."},{"issue":"1","key":"2371_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Rosmarin D, Chovatiya R, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9230. https:\/\/doi.org\/10.1038\/s41467-024-53384-1.","journal-title":"Nat Commun"},{"issue":"10","key":"2371_CR126","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/1346-8138.12978","volume":"42","author":"YM Han","year":"2015","unstructured":"Han YM, Sheng YY, Xu F, et al. Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata. J Dermatol. 2015;42(10):981\u20138. https:\/\/doi.org\/10.1111\/1346-8138.12978.","journal-title":"J Dermatol"},{"key":"2371_CR127","unstructured":"Nektar Therapeutics. Rezolve-AA phase 2b study of rezpegaldesleukin establishes proof of concept in patients with severe-to-very-severe alopecia areata [Internet]. San Francisco (CA): Nektar Therapeutics; 2025. https:\/\/ir.nektar.com\/news-releases\/news-release-details\/rezolve-aa-phase-2b-study-rezpegaldesleukin-establishes-proof."},{"key":"2371_CR128","unstructured":"ClinicalTrials.gov. A phase 2b, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA) (NCT06340360) [Internet]. Bethesda (MD): National Library of Medicine (US); 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06340360."},{"key":"2371_CR129","unstructured":"ClinicalTrials.gov. A parallel-group treatment, phase 2a, double-blind, two-arm study to investigate the efficacy and safety of farudodstat tablets compared with placebo in male or female alopecia areata participants aged 18 years and older with 30% or greater scalp hair loss (NCT05865041) [Internet]. Bethesda (MD): National Library of Medicine (US); 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05865041."},{"issue":"2 Suppl","key":"2371_CR130","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.jaad.2023.05.049","volume":"89","author":"BA King","year":"2023","unstructured":"King BA, Craiglow BG. Janus kinase inhibitors for alopecia areata. J Am Acad Dermatol. 2023;89(2 Suppl):S29\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2023.05.049.","journal-title":"J Am Acad Dermatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02371-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02371-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02371-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:06:38Z","timestamp":1790366798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02371-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":130,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2371"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02371-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jo\u00e3o Domingues has no conflicts of interest. Dr. Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a Data Monitoring Committee for Abbvie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, CAGE Bio Inc, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Inmagene Bio, Janssen Pharmaceuticals, LEO Pharma, Merck, Nektar, Novartis, Otsuka\/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc, and Ventyx Biosciences Inc. He is on speaker bureaus for Abbvie, Pfizer, Regeneron, and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Oruka, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB. Tiago Torres is an Editorial Board member of Drugs. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally to the idea for the article, conception, drafting, and revision of the manuscript. All authors read and approved the final version of the article.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}